{
    "nct_id": "NCT05722418",
    "official_title": "A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)",
    "inclusion_criteria": "1. Documented diagnosis of relapsed/refractory multiple myeloma (MM) with measurable disease (according to IMWG diagnostic criteria.)\n2. Received at least 3 prior MM treatment lines of therapy which must include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody as part of a prior line of therapy, either in monotherapy or in combination.\n3. Eastern Cooperative Oncology Group performance status grade of 0 or 1.\n4. Adequate hematologic, renal, hepatic, pulmonary, and cardiac function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Prior treatment with CAR-T cell therapy directed at any target.\n2. Autologous stem cell transplant within the last 6 weeks before lymphodepletion.\n3. Allogeneic stem cell transplant within 6 months before lymphodepletion.\n4. Known active or prior history of CNS involvement.\n5. Stroke or seizure within 6 months of signing ICF.\n6. Seropositive for or history of human immunodeficiency virus.\n7. Vaccinated with live, attenuated vaccine within 4 weeks prior to lymphodepletion.\n8. Hepatitis B infection.\n9. Hepatitis C infection.\n10. Known life-threatening allergies, hypersensitivity, or intolerance to CB-011 or its excipients.",
    "miscellaneous_criteria": ""
}